ABC (²¹²Pb-undisclosed)
Multiple Solid Tumors
DiscoveryEarly research
Key Facts
About ARTBIO
ARTBIO is pioneering a holistic approach to Alpha Radioligand Therapy (ART), combining a differentiated pipeline with proprietary isotope production and manufacturing capabilities. Founded in 2021 by the inventors of the first-ever metabolically targeted alpha therapy (Xofigo), the company is advancing multiple programs, with its lead candidate AB001 now in Phase 1/2 clinical trials for prostate cancer. Backed by a strong syndicate of top-tier life science investors, ARTBIO aims to unlock the superior efficacy and safety profile of alpha-emitting radioligands to treat a range of solid tumors.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-401 | Calidi Biotherapeutics | IND-Enabling |
| Abexinostat + Pembrolizumab | Xynomic Pharmaceuticals | Phase 1b |
| Early Cancer Detection Platform | Astrin Biosciences | Pre-clinical |
| UNO (Ultrahigh NO) | Beyond Air | Phase 1/2 |
| SonoLeukin™ | Vesselon | Pre-clinical |
| ELEPHAS-04 (Mayo Clinic) | Elephas Biosciences | Observational |
| Metastasis Companion Diagnostic | Mestastop Solutions | Prospective Clinical Trials |
| Anti-metastasis Drug Discovery | Mestastop Solutions | Preclinical/Discovery |
| Zimberelimab (AB122) | Arcus Biosciences | Phase 3 |
| ORIC-101 | ORIC Pharmaceuticals | Phase 1b |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |